Moreover, a recent study demonstrated that most CD8+ memory T cells physiologically possess upregulated levels of cytosolic phosphoenolpyruvate carboxykinase, which consistently ensures high levels of GSH and consequently quenches ROS production to favor cell survival, and GSH has been implicated in the molecular mechanism underlying this protective effect in cancer immunotherapy (Ma et al., 2018). This evidence concerns the gene CD8A and cancer.